Navigation Links
SynteractHCR Appoints Bill Pierce as Chief Information Officer and Richard Paul as Chief Medical Officer and Vice President Medical/Regulatory Affairs
Date:4/2/2013

SAN DIEGO, April 2, 2013 /PRNewswire/ -- SynteractHCR, a leading full-service contract research organization (CRO), has hired two new senior executives to support the company's growth on a global scale following its recent merger. SynteractHCR has appointed Bill Pierce as chief information officer and Richard Paul as chief medical officer and vice president medical/regulatory affairs. Both were chosen for their leadership experience and expertise in their respective fields; Pierce has held key leadership positions within the CRO as well as financial industries, and Paul has more than 23 years of drug development experience across several therapeutic areas.

(Logo: http://photos.prnewswire.com/prnh/20111108/MM02925LOGO)

As CIO, Pierce will be responsible for driving operational excellence, streamlining processes and delivering high returns for invested capital. He brings a strong foundation in the CRO industry and is very experienced across clinical data management platforms and technologies. He gained leadership experience across various industries, including his last position at INC Research as chief information officer. Previously he served as vice president both for Fidelity Investments and Goldman Sachs, among other leadership positions. Pierce received his degree from Boston University.

In his role as CMO, Dr. Paul will be providing global leadership and oversight for medical safety and regulatory affairs. He brings more than 23 years of clinical research, regulatory affairs, medical safety and strategic drug development experience to his new role. Prior to joining SynteractHCR, Paul held positions with QRxPharma as executive vice president of drug development where he had global responsibility for clinical research and regulatory affairs. He also served as senior vice president of global regulatory affairs at ICON Clinical Research. Paul earned his MD degree from the University of Barcelona and conducted his postgraduate medical training at Rutgers University and Harvard School of Medicine.

According to Wendel Barr , CEO of SynteractHCR, the two new hires will be instrumental in driving the company's plans for growth to meet the increasingly complex needs of its clients.

"After two decades of operations, we are known for offering our clients individualized services tailored to their specific needs. With their impressive industry experience, Bill and Richard provide additional valuable assets to our company. Leading our Information Technology group, Bill will leverage technology to drive efficiency across the projects we support and overall business productivity. Paul's expertise in medical, safety, drug development and regulatory affairs will ensure that across the continuum of our service offering, we maintain the highest quality standards with product approval the objective. I am certain that as excellent leaders, Bill and Rich will help the company grow, to further expand our offerings on a global scale." 

SynteractHCR has been formed from the merger of Synteract and Harrison Clinical Research (HCR), announced earlier this month. The newly expanded company operates from 16 locations worldwide and will provide top tier international capabilities to support clinical trials globally, from emerging products through post-marketing. 

About SynteractHCR (www.synteracthcr.com)
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. With its "Shared Work – Shared Vision" philosophy SynteractHCR provides customized Phase I through IV services collaboratively and cost effectively ensuring on-time delivery of quality data so clients get to decision points faster. Operating in 16 countries, SynteractHCR delivers trials internationally, offering expertise across multiple therapeutic areas including notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications.

CONTACT:
Antonia Genov
antonia@clearpointagency.com
760-230-2424


'/>"/>
SOURCE SynteractHCR
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
2. Varian Medical Systems Appoints Deepak "Dee" Khuntia M.D. Vice President of Medical Affairs
3. Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors
4. Chimerix Appoints Michael D. Rogers, Ph.D., as Chief Development Officer
5. Vermillion Appoints Thomas McLain as President and Chief Executive Officer
6. Echo Therapeutics Appoints Robert Doman to Board of Directors
7. CIVCO Appoints Hap Peterson Vice President of North American Sales for Radiation Oncology
8. Amedica Appoints Karl Farnsworth as Chief Financial Officer
9. Marken Appoints New Directors To Board
10. Aquavit Pharmaceuticals Inc. Appoints David Shafer, MD., FACS., New Chief Medical Technology Officer
11. Trovagene Appoints Mark Erlander, Ph.D. as Chief Scientific Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 10, 2016 CERS ), Medivation, Inc. ... ) and Celldex Therapeutics, Inc. (NASDAQ: CLDX ). ... Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS ) and Celldex Therapeutics, ... Orphan Drug Designations become vitally important in the development of ... drugs and biologics which are defined as those intended for ...
(Date:2/10/2016)... /PRNewswire/ - The President of New Venture Medical, ... an anti-radiation product from their Research and Development ... treatment of cancer using radiation and the treating ... the healing of radiation burns, even when open ... the healthy cells from radiation damage. It selectively ...
(Date:2/10/2016)... , Feb. 10, 2016  Silicon Biosystems Menarini ... products that help uncover the biological complexities of ... Inc., a developer of innovative technologies for genomics ... partnership aimed at enabling translational researchers to obtain ... couple hundred tumor and normal cells in an ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 10, 2016 , ... Everseat has joined the award-winning Allscripts ... physicians. The integration will enable Allscripts users to post open appointments to the ... app. , The partnership gives Everseat substantial added power to help Allscripts meet ...
(Date:2/10/2016)... ... February 10, 2016 , ... Workrite Ergonomics this week announced the launch ... mounts ever. , “Our goal was to develop a product from the ground ... we have ever created.” said Darren Hulsey, Product Manager for Workrite Ergonomics. “The ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Anxiety of older ... the start of Medicare Part D a decade ago, according to The Senior ... older adults on how they are coping with rapidly rising costs. “The implications ...
(Date:2/10/2016)... ... February 09, 2016 , ... ... Face and Body Specialists are delighted to welcome a new addition to their ... Face and Body Specialists as a nurse practitioner performing cosmetic procedures ...
(Date:2/10/2016)... ... February 10, 2016 , ... It’s that time of year when most ... of the Interscholastic Athletic Association of Maryland (IAAM), Hall of Fame athlete and Garrison ... are cast aside. , That’s why one of her first decisions when her IAAM ...
Breaking Medicine News(10 mins):